Apellis Pharmaceuticals IncChange company Symbol lookupSelect an option...APLS Apellis Pharmaceuticals IncRNXT RenovoRx IncBNTX BioNTech SEARTW Art's Way Manufacturing Co IncARIZU Arisz Acquisition CorpOSH Oak Street Health IncLESL Leslie's IncAAPL Apple IncBYM BlackRock Municipal Income Quality TrustDLA Delta Apparel IncGo
Change company Symbol lookup
Select an option...
APLS Apellis Pharmaceuticals Inc
RNXT RenovoRx Inc
BNTX BioNTech SE
ARTW Art's Way Manufacturing Co Inc
ARIZU Arisz Acquisition Corp
OSH Oak Street Health Inc
LESL Leslie's Inc
AAPL Apple Inc
BYM BlackRock Municipal Income Quality Trust
DLA Delta Apparel Inc
Health Care : Biotechnology | Mid Cap Growth
Company profileApellis Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system. Its SYFOVRE (pegcetacoplan injection) is the Company’s approved treatment for geographic atrophy secondary to age-related macular degeneration (GA). The Company’s EMPAVELI (pegcetacoplan) is the treatment of paroxysmal nocturnal hemoglobinuria (PNH). Its Aspaveli (pegcetacoplan) is the treatment of adults with PNH who are anemic after treatment with a C5 inhibitor for at least three months. Systemic pegcetacoplan has an approval for the treatment of PNH in Saudi Arabia, Australia, and the United Kingdom. Systemic pegcetacoplan markets under the trade name EMPAVELI in the United States, Saudi Arabia and Australia and Aspaveli in the European Union and United Kingdom.
|
|
|
|
| |
| Latest Earnings Met Consensus (Q4 ending 12/2022) | Next Earnings Announcement | ||||
|---|---|---|---|---|---|
| Q4 Non-GAAP earnings GAAP vs. Non-GAAP EarningsTD Ameritrade displays two types of stock earnings numbers, which are calculated differently and may report different values for the same period. GAAP earnings are the official numbers reported by a company, and non-GAAP earnings are adjusted to be more readable in earnings history and forecasts. Announced February 21, 2023 | -$1.50 | Q4 Estimate range of 14 analysts | -$2.94 to -$1.09 | Q1 Earnings will announce | (Unconfirmed) May 2, 2023 |
Quarterly Earnings History and Estimates
Show high-low estimates
Draw trendlines
Draw up to 3 lines inside the chart.
APLS's fiscal year ends in December
Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.
Information provided by Copyright © 2023. All rights reserved.
Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.
Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.